Angiosarcoma Presenting as a Chronic Non‐Healing Lower Extremity Ulcer in Lymphoedema: A Challenge Authors: Megan Koch, Leena Hani, Erica Friedman, Frank L. Ross Published: 2026 ABSTRACT ABSTRACTCutaneous angiosarcoma is a rare and aggressive malignancy that may arise in chronic lymphoedema. Its presentation as a non‐healing ulcer can lead to delayed diagnosis. We describe an atypical case of angiosarcoma presenting as a chronic lower extremity ulcer in the setting of chronic lymphoedema and to highlight the importance of early biopsy. We report on the clinical course, diagnostic evaluation, treatment, and outcome of a patient with chronic lymphoedema who developed a persistent ulcer. A 74‐year‐old woman with longstanding lower extremity lymphoedema developed a non‐healing ulcer initially managed as cellulitis and venous ulceration. Due to failure of conservative therapy, biopsy was performed and revealed angiosarcoma. The patient underwent surgical resection and adjuvant radiotherapy, remaining disease‐free for over 4 years before recurrence and eventual death. Malignancy should be considered in chronic non‐healing ulcers, especially in the setting of longstanding lymphoedema. Early biopsy is essential to avoid delayed diagnosis and improve outcomes. Introduction Cutaneous angiosarcoma is a rare and aggressive malignancy that arises from vascular or lymphatic endothelium and may occur in association with chronic lymphoedema [1]. Although uncommon, it most frequently involves skin and soft tissues and can present with variable and often non‐specific clinical findings [2]. In patients with chronic lymphoedema, angiosarcoma may manifest as a non‐healing ulcer, which can lead to delayed recognition and misdiagnosis as more common benign wound aetiologies. Early identification is critical given its aggressive behaviour and poor prognosis. Stewart‐Treves syndrome (STS), or lymphangiosarcoma, is a rare form of angiosarcoma associated with chronic lymphoedema and was originally described in the upper extremities of women following radical mastectomy for breast cancer [3]. Although the majority of cases occur in post‐mastectomy lymphoedema, angiosarcoma may arise in lymphoedema of any aetiology. Cases arising in chronic lower extremity lymphoedema unrelated to prior malignancy or cancer treatment are particularly uncommon and have been reported far less frequently in the literature. Involvement of the lower extremity is uncommon, representing a small minority of cases [1]. These tumours are characterised by an aggressive clinical course and poor prognosis, often related to delays in diagnosis and early metastatic potential [4]. We present a case of cutaneous angiosarcoma arising in chronic lower extremity lymphoedema, highlighting the diagnostic challenges associated with atypical presentations. Case Presentation A 74‐year‐old woman with class III obesity and a 20‐year history of bilateral chronic idiopathic lymphoedema presented with an ulcer on the anterior aspect of the left lower limb that had progressed over several months. The patient had previously undergone vascular evaluation approximately 8 years before presentation, which demonstrated no evidence of venous obstruction, venous insufficiency, deep venous thrombosis, or peripheral arterial disease. Her oedema was considered consistent with chronic idiopathic lymphoedema in the setting of obesity. Prior management included compression garments, leg elevation, manual lymphatic drainage, and a home lymphoedema pump. Formal lymphoedema staging was not documented in the available medical record. Physical examination revealed 3+ non‐pitting oedema of the bilateral lower extremities, left greater than right, and a 2 × 1 cm open ulcer on the anterior left shin draining clear fluid and surrounded by erythema (Figure 1). She was initially treated with oral antibiotics, local wound care and elevation/compression. Despite outpatient management, the ulcer and surrounding erythema worsened, and she was admitted for presumed cellulitis and treated with broad‐spectrum intravenous antibiotics and wound care. Although there was partial improvement, the ulcer and erythema did not fully resolve. Dermatology consultation was obtained to evaluate for pyoderma gangrenosum; however, the clinical appearance was not consistent with this diagnosis, and conservative management was continued. Initial presentation of a chronic non‐healing ulcer on the anterior aspect of the left lower extremity. Over the ensuing months, the patient continued local wound care and intermittent courses of oral antibiotics. In‐person evaluation was deferred due to the COVID‐19 pandemic. The patient initially declined her dermatologist's recommendation for biopsy because of concern for wound enlargement and delayed healing in the setting of chronic lymphoedema. Eight months after initial presentation, she was referred to a wound care specialist for persistent ulceration despite maximal local wound care and compression (Figure 2). Overview of the left lower extremity ulcer at initial wound care evaluation prior to biopsy. On evaluation by the wound care specialist, a wedge biopsy was performed given the chronic, progressive course and ulcerated appearance inconsistent with a venous insufficiency ulcer or pyoderma gangrenosum. Histopathology revealed cutaneous angiosarcoma with epithelioid features, extending to the base of the specimen (Figure 3). Immunohistochemical staining demonstrated positivity for CD31, FLI1, ERG, Factor VIII (patchy) and D2‐40, while tumour cells lacked immunoreactivity for HHV8 (Figure 4). Histopathologic findings of cutaneous epithelioid angiosarcoma. (A) Lower‐power H&E photomicrograph demonstrating large atypical cells with prominent nucleoli and atypical mitotic figures (white arrow). (B) Higher‐power H&E photomicrograph highlighting similar findings including marked cytologic atypia and an atypical mitotic figure. Immunohistochemical characterisation of cutaneous epithelioid angiosarcoma. (A) ERG (×20) immunohistochemical stain demonstrating strong diffuse nuclear staining consistent with endothelial differentiation. (B) CD31 (×20) immunohistochemical stain demonstrating diffuse membranous staining consistent with endothelial differentiation. Upon evaluation by a surgical oncologist, the patient was found to have a 3 × 2 cm shallow ulcer over the left shin with a fibrinous, exudative base. No satellite lesions or regional adenopathy were identified. Baseline staging with contrast‐enhanced PET/CT demonstrated no regional or distant disease. Contrast‐enhanced MRI of the left lower extremity revealed focal skin thickening and irregularity along the anterior distal lower leg measuring 4.7 × 4.7 cm, confined to the skin without invasion of subcutaneous tissues. The patient subsequently underwent radical resection with > 1 cm margins encompassing the lesion and surrounding erythema (Figure 5). The resected specimen measured 7 × 7 cm and extended to the underlying tibial periosteum, with placement of a dermal substitute. Final pathology demonstrated residual cutaneous epithelioid angiosarcoma involving the dermis and subcutaneous tissues, measuring 3.1 × 2.5 cm, with involvement of the proximal and distal margins and a clear deep margin. She underwent re‐excision with 1 cm margins around the prior incision. Pathology again demonstrated residual angiosarcoma involving the dermis and subcutaneous tissues, extending to within 0.5 mm of the peripheral margins and focally to the deep margin. Further resection was not pursued following multidisciplinary tumour board discussion. Postoperative appearance following wide local excision of the left lower extremity lesion. The patient completed adjuvant radiotherapy with 6000 cGy in 30 fractions. Following completion of radiotherapy, she developed persistent lower extremity oedema with delayed wound healing, which was managed with staged debridement, compression therapy with Unna boot, and subsequent transition to compression stockings (Figure 6). The wound subsequently healed (Figure 7). She remained disease‐free on surveillance imaging and clinical examination until 4 years and 4 months after initial resection, when she developed erythematous papules on the left lower leg (Figure 8). Punch biopsy of one lesion confirmed recurrent angiosarcoma. Contrast‐enhanced whole‐body PET/CT demonstrated multiple hypermetabolic cutaneous and subcutaneous nodules in the left lower leg, between the knee and thigh, consistent with biopsy‐proven in‐transit metastases (Figure 9). No regional or distant metastatic disease was identified. Systemic therapy with paclitaxel was initiated and initially well tolerated, with clinical response; however, treatment was discontinued 5 months later because of progressive locoregional disease. Subsequent imaging demonstrated recurrent cutaneous and subcutaneous angiosarcoma confined to the left lower extremity without evidence of nodal or distant metastatic disease. The patient experienced progressive oedema, wound drainage, and overall clinical decline, was transitioned to hospice care, and died approximately 5 years after the initial diagnostic biopsy. Postradiotherapy wound with delayed healing, managed with debridement and compression therapy. Healed left lower extremity following wound care and compression therapy. Recurrent angiosarcoma presenting as erythematous papules consistent with in‐transit metastases on the left lower extremity. Whole‐body PET/CT demonstrating extensive FDG‐avid cutaneous and subcutaneous lesions throughout the left lower extremity, consistent with in‐transit metastases of angiosarcoma. No distant metastatic disease is identified. Discussion Stewart‐Treves syndrome (STS) is a rare and often fatal condition in which angiosarcoma develops in the setting of chronic lymphoedema. It was first described in 1948 by Stewart and Treves in association with post‐mastectomy lymphoedema of the upper extremities [1, 3]. Although the majority of reported cases occur in this context, angiosarcoma may arise in chronic lymphoedema of any aetiology. More than 400 cases have been reported in the literature, with an incidence estimated between 0.07% and 0.45% among women surviving breast cancer for at least 5 years following mastectomy [5]. Despite its rarity, STS carries a poor prognosis due to its aggressive behaviour and tendency for delayed diagnosis. Chronic lymphoedema results from impaired lymphatic drainage and may be primary (congenital/hereditary) or secondary (acquired) [1, 6]. While most commonly associated with postmastectomy states, angiosarcoma may develop in lymphoedema of various aetiologies, including obesity, venous stasis, malignancy and prior surgical intervention [1]. Notably, STS has been reported to occur earlier in the course of chronic lymphoedema and is associated with a worse prognosis compared to other malignancies arising in lymphoedematous tissue [7]. Despite the presence of chronic oedema, STS remains rare, suggesting that additional factors beyond lymphoedema alone may contribute to its development [5]. Radiation therapy for breast cancer may contribute to the development of lymphoedema through axillary lymph node fibrosis and impaired lymphatic drainage [6]. In addition, radiation exposure has been associated with an increased risk of secondary angiosarcoma of the breast and chest wall, with one study reporting a relative risk of 15.9 compared to non‐irradiated patients [8]. Axillary lymph node dissection further increases the risk of upper extremity lymphoedema, particularly when combined with multimodal therapy including chemotherapy, surgery and radiation [9]. Although advances in surgical techniques—such as the use of sentinel lymph node biopsy—have reduced the incidence of treatment‐related lymphoedema, it remains a significant clinical problem [10]. Importantly, lymphoedema is not limited to breast cancer and may also occur following treatment of gynaecologic, urologic, and cutaneous malignancies, including melanoma and lymphoma [11, 12]. Several theories have been proposed to explain the relationship between STS and chronic lymphoedema. One hypothesis suggests that impaired lymphatic drainage leads to accumulation of protein‐rich interstitial fluid, promoting cellular degeneration and the release of growth factors that stimulate angiogenesis, including vascular endothelial growth factor (VEGF). This pro‐angiogenic environment may contribute to oncogenesis. At the molecular level, MYC is a proto‐oncogene located on chromosome 8q24 that promotes tumorigenesis through increased cellular proliferation, growth, and loss of differentiation. High‐level MYC amplification has been identified as a characteristic molecular alteration in secondary angiosarcomas arising in the setting of chronic lymphoedema and prior radiation exposure. Udager et al. demonstrated strong MYC protein expression in the majority of radiation‐associated angiosarcomas and Stewart‐Treves syndrome‐associated angiosarcomas, whereas atypical vascular lesions were predominantly negative. Notably, de novo angiosarcomas demonstrated variable MYC expression, with higher‐grade tumours showing significantly greater expression than low‐grade tumours. Shon et al. further demonstrated MYC amplification and protein overexpression in a subset of primary cutaneous angiosarcomas, confirming that MYC dysregulation is not limited to secondary disease. However, MYC amplification and overexpression were not associated with histologic grade, clinical outcome, or survival, suggesting that MYC activation may represent one component of a more complex molecular pathway driving angiosarcoma development. Taken together, these findings support a role for MYC‐driven tumorigenesis in Stewart‐Treves syndrome and suggest that malignant transformation likely results from the interplay of chronic lymphatic dysfunction, persistent tissue inflammation, angiogenic signalling and acquired genetic alterations [13, 14, 15]. Diagnosis of cutaneous angiosarcoma can be challenging due to its variable and often non‐specific clinical presentation, which may mimic a range of benign and malignant conditions. A high index of suspicion and early consideration of biopsy are essential given the aggressive nature of the disease and its poor prognosis. In this case, concern for impaired wound healing in the setting of chronic venous insufficiency and lymphoedema was weighed against the need for timely diagnosis. Benign differential diagnoses include pyoderma gangrenosum, cellulitis, and lymphangioma; while malignant considerations include melanoma, Kaposi sarcoma (KS), basal cell carcinoma, and squamous cell carcinoma [10]. KS may be particularly difficult to distinguish from angiosarcoma due to overlapping clinical features and shared endothelial origin [16, 17]. However, KS is strongly associated with human herpesvirus 8 (HHV‐8) and immunohistochemical detection of HHV‐8 latent nuclear antigen is a useful diagnostic marker for Kaposi sarcoma [18, 19]. In the present case, tumour cells lacked immunoreactivity for HHV8, supporting the diagnosis of angiosarcoma rather than Kaposi sarcoma. Definitive diagnosis of cutaneous angiosarcoma relies on histopathologic evaluation, with immunohistochemical staining demonstrating endothelial markers such as CD31, CD34, Factor VIII–related antigen, and VEGF. Among these, CD31 is considered the most sensitive and specific marker. Imaging with MRI and/or CT is useful for assessing tumour extent and local invasion once the diagnosis is established [2]. The standard of care for cutaneous angiosarcoma is surgical resection, with or without adjuvant radiotherapy and chemotherapy, with negative margins remaining the cornerstone of treatment. Additional therapeutic options include targeted VEGF therapy, tyrosine kinase inhibitors, and immunotherapy [2]. Several prognostic factors have been associated with poorer outcomes, including tumour size > 5 cm, depth of invasion, high mitotic rate, positive surgical margins, and the presence of metastases or recurrence [20]. Overall prognosis remains poor, with an average survival of approximately 37 months and as little as 9 months in patients with advanced disease [21]. Beyond the challenges of diagnosis, management is often complicated by limited response to conventional cytotoxic chemotherapy, morbidity associated with extensive surgical resection, and difficulty achieving histologically negative margins due to the infiltrative nature of the disease. However, treatment strategies continue to evolve, with emerging evidence supporting the use of immunotherapy—such as pembrolizumab, ipilimumab and nivolumab—either alone or in combination with chemotherapy (e.g., paclitaxel plus avelumab in unresectable disease) [22, 23]. This case highlights the importance of maintaining a low threshold for biopsy in chronic non‐healing ulcers, particularly in patients with underlying lymphoedema, to facilitate early diagnosis and improve outcomes. Conclusion Despite advances in understanding and management, cutaneous angiosarcoma remains associated with high recurrence and mortality. In this case, a patient with longstanding lower extremity lymphoedema developed angiosarcoma presenting as a chronic non‐healing ulcer, with delayed diagnosis and eventual disease progression. This highlights the importance of maintaining a low threshold for biopsy in chronic non‐healing ulcers, particularly in patients with underlying lymphoedema. Early diagnosis and multidisciplinary management are essential to improve outcomes in this high‐risk population. Funding The authors have nothing to report. Ethics Statement Ethical approval was not required for this case report in accordance with institutional policies. Conflicts of Interest The authors declare no conflicts of interest.